Literature DB >> 22092396

Focal active colitis: a prospective study of clinicopathological correlations in 90 patients.

Sharan Shetty1, Salim M Anjarwalla, Jyoti Gupta, Chris J W Foy, Ian S Shaw, Roland M Valori, Neil A Shepherd.   

Abstract

AIMS: Considerable controversy exists about the clinical implication of a diagnosis of focal active colitis (FAC). The aim of this study was to assess clinicopathological correlations of FAC in 90 adults, representing the largest and only prospective series of FAC. METHODS AND
RESULTS: Patients were assessed by comprehensive clinical follow-up and questionnaires. Fifteen histopathological features were scored and correlated with clinical outcome. In 24% of patients drugs, especially NSAIDs, were implicated. Infection was a probable cause in 19%. In 14 patients (15.6%), predominantly women, a diagnosis of chronic inflammatory bowel disease was ultimately made. Most were Crohn's disease, but this is the first study in which FAC has presaged an ultimate diagnosis of ulcerative colitis in adults (in two patients). A specific subtype of FAC, termed basal FAC, was significantly associated with drugs. These excepted, this study has found no histopathological parameters of FAC, such as amount, location and/or distribution, to correlate with clinical outcome or allowed selection of those patients more likely to show subsequent evidence of chronic inflammatory bowel disease.
CONCLUSION: This study has provided powerful information on the implication of a diagnosis of FAC. In a small but not inconsiderable case number, the ultimate diagnosis will be chronic inflammatory bowel disease.
© 2011 Blackwell Publishing Limited.

Entities:  

Mesh:

Year:  2011        PMID: 22092396     DOI: 10.1111/j.1365-2559.2011.04019.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  9 in total

Review 1.  Biopsy interpretation of colonic biopsies when inflammatory bowel disease is excluded.

Authors:  Tze S Khor; Hiroshi Fujita; Koji Nagata; Michio Shimizu; Gregory Y Lauwers
Journal:  J Gastroenterol       Date:  2012-02-10       Impact factor: 7.527

2.  Lower gastrointestinal endoscopy: guidance on indications for biopsy.

Authors:  A C Bateman; P Patel
Journal:  Frontline Gastroenterol       Date:  2013-12-20

Review 3.  Diagnostic dilemmas in chronic inflammatory bowel disease.

Authors:  Maurice B Loughrey; Neil A Shepherd
Journal:  Virchows Arch       Date:  2017-11-04       Impact factor: 4.064

4.  Histopathological findings of extra-ileal manifestations at initial diagnosis of Crohn's disease-related ileitis.

Authors:  Ian S Brown; Gregory C Miller; Mark L Bettington; Christophe Rosty
Journal:  Virchows Arch       Date:  2016-09-03       Impact factor: 4.064

Review 5.  Gut inflammation induced by drugs: Can pathology help to differentiate from inflammatory bowel disease?

Authors:  Naoimh Herlihy; Roger Feakins
Journal:  United European Gastroenterol J       Date:  2022-05-28       Impact factor: 6.866

Review 6.  Towards a new paradigm of microscopic colitis: Incomplete and variant forms.

Authors:  Danila Guagnozzi; Stefania Landolfi; Maria Vicario
Journal:  World J Gastroenterol       Date:  2016-10-14       Impact factor: 5.742

7.  Colorectal Disorders in Acute Human Immunodeficiency Virus Infection: A Case Series.

Authors:  Theppharit Panichsillapakit; Derek Patel; Joanne Santangelo; Douglas D Richman; Susan J Little; Davey M Smith
Journal:  Open Forum Infect Dis       Date:  2016-01-29       Impact factor: 3.835

Review 8.  Histological evaluation in ulcerative colitis.

Authors:  Tom C DeRoche; Shu-Yuan Xiao; Xiuli Liu
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-06-18

9.  Challenges in the diagnosis of ulcerative colitis with concomitant bacterial infections and chronic infectious colitis.

Authors:  Wei-Chen Lin; Chen-Wang Chang; Ming-Jen Chen; Cheng-Hsin Chu; Shou-Chuan Shih; Tzu-Chi Hsu; Horng-Yang Wang
Journal:  PLoS One       Date:  2017-12-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.